scispace - formally typeset
C

Charles D. Mitchell

Researcher at University of Miami

Publications -  85
Citations -  3733

Charles D. Mitchell is an academic researcher from University of Miami. The author has contributed to research in topics: Population & Tuberculosis. The author has an hindex of 31, co-authored 84 publications receiving 3517 citations. Previous affiliations of Charles D. Mitchell include University of Minnesota & Boston Children's Hospital.

Papers
More filters
Journal ArticleDOI

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection.

TL;DR: The experience at Jackson Memorial Hospital in Miami, Florida, with 172 children who were given diagnoses of perinatally acquired infection with human immunodeficiency virus ty... is described.
Journal ArticleDOI

Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel

TL;DR: The definitions presented in this article are intended for use in clinical research to evaluate diagnostic assays and not for individual patient diagnosis or treatment decisions.
Journal ArticleDOI

Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

TL;DR: The most common adverse reaction was a low incidence of peripheral vein irritation; no serious toxicity could be definitely attributed to acyclovir treatment even in these seriously ill patients.
Journal ArticleDOI

Renal disease in children with the acquired immunodeficiency syndrome.

TL;DR: Of 155 children with the acquired immunodeficiency syndrome (AIDS) whom the authors evaluated during a 6 1/2-year period, 12 were found to have proteinuria, and 10 of the 12 patients with proteinuria died during this period.
Journal ArticleDOI

Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients

TL;DR: Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous herpes simplex virus infections in immunocompromised patients.